[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-pancreatic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-pancreatic-neoplasms":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100504403",false,"NCT05847855","Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors","Inclusion Criteria:\n\n* Age 18 and above, regardless of gender;\n* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* No obvious surgical contraindications;\n* Able to comply with research plans, follow-up plans, and other protocol requirements;\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Currently diagnosed with other types of tumors or any cancer history;\n* Diagnosed with familial syndromes;\n* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;\n* Recipient of blood transfusion within 30 days prior to study blood draw;\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n* Poor health condition and not suitable for blood draw;\n* Any other disease\u002Fcondition deemed not suitable for study enrollment by researcher.",true,"ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.",[24,25],"Pancreatic Neuroendocrine Tumor","Solid Pancreatic Neoplasms",[27,28,29,30,31],"Pancreatic neuroendocrine tumor","cell-free DNA","fragmentomics","early detection","Solid pancreatic neoplasms","RECRUITING","2026-03-23",{"date":35,"type":36},"2026-03-25","ACTUAL",{"date":38,"type":36},"2023-02-27",{"date":40,"type":20},"2026-06-30",{"name":42,"class":43},"Fudan University","OTHER",2,""]